{"id":"W4400929921","doi":"10.1016/j.esmoop.2024.103646","title":"Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Incyte; Mirati Therapeutics; Jounce Therapeutics; Regeneron Pharmaceuticals; Daiichi-Sankyo; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tremelimumab; Durvalumab; Head and neck squamous-cell carcinoma; Medicine; CTLA-4; Oncology; PD-L1; Immunotherapy; Cytotoxic T cell; Internal medicine; Cancer research; Head and neck cancer; T cell; Immunology; Cancer; Immune system; Ipilimumab; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007146351,0.0001601919,0.0005282058,0.00009052154,0.00003763113,0.00005109901,0.00009468596,0.00003929311,0.00007665403],"category_scores_gemma":[0.00003129309,0.0001149758,0.00004889101,0.0002104413,0.0001305537,0.0001442301,0.0001076524,0.0002310815,0.000001731676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006024133,"about_ca_system_score_gemma":0.000150371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003056078,"about_ca_topic_score_gemma":0.00329111,"domain_scores_codex":[0.9986629,0.0002132935,0.0004152131,0.0003841426,0.0001609412,0.00016348],"domain_scores_gemma":[0.9993391,0.0002176161,0.00008003396,0.000245792,0.00003039764,0.00008704891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3009613,0.01510527,0.4936641,0.0007856194,0.0004087401,0.0006618766,0.004203075,4.256706e-7,0.000510587,0.00000608248,0.0002519854,0.183441],"study_design_scores_gemma":[0.1035885,0.02472945,0.8675109,0.0003220751,0.0003354462,0.00002868647,0.0008543545,0.001322294,0.0004027634,0.000003685289,0.0007347643,0.0001670991],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962186,0.0006921011,0.000009786093,0.0003729547,0.0001257954,0.002122535,0.00002891809,0.00001289842,0.0004164134],"genre_scores_gemma":[0.9993725,0.0001084008,0.0001630587,0.00006342116,0.00001567573,0.00002725775,0.0000114395,0.0000203007,0.0002178912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3738468,"threshold_uncertainty_score":0.4688578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04684865456165723,"score_gpt":0.3826954400880829,"score_spread":0.3358467855264257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}